LUND, Sweden, Aug. 25, 2015 /CNW/ -- BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that its platform bone void filler, CERAMENT™ with antibiotics, will have a significant presence at the upcoming 34th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) taking place September 10-12 in Lisboa, Portugal. The annual meeting will feature twelve presentations and posters highlighting the outstanding long-term clinical benefits of CERAMENT™|G, the first CE-marked antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.
EBJIS is a European association of orthopedic surgeons, trauma surgeons, infection specialists and microbiologists. The aim of the Society is to promote the knowledge of all infections affecting the Musculoskeletal system (bone and joint infections), and to promote the prevention and treatment of these infections.
Osteomyelitis (bone infection) is a $1.7 billion market where prolonged, long-term antibiotic therapy, repeated unsuccessful surgical interventions and the threat of amputation are the current standard of care. An increase in prosthetic infections, diabetic foot ulcers, war injuries, high-energy sports injuries, and antibiotic resistance fuel the need for more effective therapeutic solutions.
"We are especially excited about this year's EBJIS program and the prominent role of CERAMENT™ with antibiotics," said Lloyd Diamond, CEO of BONESUPPORT™. "CERAMENT™IG represents a significant advancement in the management of osteomyelitis and we are encouraged by both the clinical outcomes and high demand for the product in Europe. We remain on track for initiating FDA approval of CERAMENT™IG in the USA with the goal of making this novel solution more widely available."
To view the complete program, go to: http://www.ebjis2015.org/ .
BONESUPPORT™ is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT™|G and CERAMENT™|V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G and CERAMENT™|V are not available in the United States.
CERAMENT™ is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENT™ is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT™ spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 10,000 patients have been treated with CERAMENT™. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT™ please visit www.bonesupport.com.
Chief Financial Officer
Phone +46 46 286 53 60
PR 0449-01 en